ClinicalTrials.gg
CompletedNCT01098266Updated Sep 17, 2019Results posted

NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

A Phase 3 interventional study of NGR-hTNF plus Best Investigator's Choice (BIC) and Placebo plus Best Investigator's Choice (BIC) in Malignant Pleural Mesothelioma, sponsored by AGC Biologics S.p.A.. Completed at 49 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-17.

Sponsored by AGC Biologics S.p.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies in Mesothelioma, Malignant with a site in Italy — 7 open to participants now, 12 under way, 2 of them phase 3. Mesothelioma, Malignant · Italy.

Enrollment
3rd of 33
400 · median 88
Started
2010
the only one that year
Phase 3
7 of 45
1 open now
Registered
8th of 45
by date
Lead sponsor
3 of 45
AGC Biologics S.p.A.

Among the 45 studies in Mesothelioma, Malignant with a site in Italy, this one is the 3rd largest by enrollment of the 33 interventional ones that give a count, is the only one that started in 2010, is one of 7 in phase 3, and was the 8th registered.

Mesothelioma, Malignant

339 studies on the registry are indexed under Mesothelioma, Malignant; 63 are open to participants now.

Browse Mesothelioma, Malignant studies →

Open to participants now

7 of the 45 studies in Mesothelioma, Malignant with a site in Italy are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 54 Mesothelioma, Malignant studies recruiting now, 42 (78%) set no upper age limit and 5 (9%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Mesothelioma, Malignant with a site in Italy, or all of them as a file.
02

Study summary

The main objective of the trial is to document the efficacy of NGR-hTNF administered at low dose weekly in advanced Malignant Pleural Mesothelioma patients previously treated with a pemetrexed-based chemotherapy regimen.

Read the detailed description

Currently, there are no regulatory-approved or widely accepted treatment options for patients failing a standard pemetrexed-based chemotherapy regimen.

For this reason, the best supportive care (BSC) alone might be considered as a standard reference for a randomized phase III trial in this setting.

However, single-agent chemotherapeutic agents (such as doxorubicin,gemcitabine, or vinorelbine) with a well-documented safety profile and antitumor activity are also used in clinical practice.

Therefore, the best investigator's choice (BIC) between either best supportive care alone or combined with a few selected single-agent chemotherapy (including doxorubicin, gemcitabine, or vinorelbine) might be considered as an acceptable reference arm as well in this setting.

The current phase III study aims to show a superior efficacy in terms of overall survival duration of NGR-hTNF 0.8 µg/mq weekly plus BIC versus placebo plus BIC in advanced MPM patients progressing after a standard pemetrexed-based chemotherapy.

03

Conditions studied

  • Malignant Pleural Mesothelioma

Keywords

  • MPM
  • NGR-hTNF
  • NGR-hTNF plus BIC
  • Randomized double-blind phase III study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Histologically or cytological confirmed malignant pleural mesothelioma of any of the following subtype: epithelial, sarcomatoid, mixed, or unknown
  • Prior treatment with no more than one systemic pemetrexed-based chemotherapy regimen administered for advanced or disease. Prior use of a biological agent in combination with a pemetrexed-based regimen and prior administration of intrapleural cytotoxic agents are allowed. Patients who have previously received anthracyclines should not receive doxorubicin
  • Performance Status 0 - 2
  • of ≥ 12 weeks
  • Adequate baseline bone marrow, hepatic and renal function, defined as follows:

    1. Neutrophils ≥ 1.5 x 109/L; ≥ 100 x 109/L; ≥ 9 g/dL
    2. ≤ 1.5 x
    3. and/or ALT ≤ 2.5 x ULN in absence of liver metastasis or ≤ 5 x ULN in presence of liver metastasis
    4. Serum creatinine \< 1.5 x ULN
  • Measurable or non- according to MPM-modified criteria
  • Patients may have had prior therapy providing the following conditions are met:

    1. Surgery: of 14 days
    2. Systemic and radiation anti-tumor therapy: wash-out period of 28 days
  • Patients must give written to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Patients must not receive any other agents while on study
  • Patients with myocardial infarction within the last six months, unstable angina, (NYHA) grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication
  • Uncontrolled hypertension
  • (congenital or acquired) > 450 ms
  • History or evidence upon physical examination of CNS disease unless adequately treated (e.g., primary brain tumor, any , seizure not controlled with standard medical therapy, or history of stroke)
  • Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol
  • Known /allergic reaction to human albumin preparations or to any of the
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol
  • Pregnancy or lactation
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
400 participants (actual)

Study arms

  • Experimental
    A: NGR-hTNF + BIC

    NGR-hTNF plus Best Investigator's Choice

    Drug: NGR-hTNF plus Best Investigator's Choice (BIC)

  • Placebo comparator
    B: Placebo+BIC

    Placebo plus Best Investigator's Choice

    Drug: Placebo plus Best Investigator's Choice (BIC)

Interventions

  • DrugNGR-hTNF plus Best Investigator's Choice (BIC)

    * NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs. * Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis * Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination: 1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)

    Also known as: NGR-hTNF+BIC

  • DrugPlacebo plus Best Investigator's Choice (BIC)

    * Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs. * Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis * Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination: 1. Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles 2. Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles 3. Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)

    Also known as: Placebo+BIC

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Defined as the time from the date of randomization until the date of death due to any cause or the last date the patient was known to be alive

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, wichever came first, assesed up to 48 months

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Defined as the time from the date of randomization until disease progression, or deathdue to any couse or the last patient was konwn to be alive. Progression is defined usind Response Evaluation Criteria In Solid Tumors Criteria (Recist v1.1), as a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition torelative increase of 20% the sum must also demonstrate an absolute increase of at least 5 mm. In addition the appearance of one or more new lesions was also considered progression

    Time frame: From the date of randomization until the date of first documented progression or date of death from any cause, wichever came first, assessed up to 48 months

  2. Disease Control Rate (DCR)

    Disease control rate (DCR), defined as the percentage of patients who have a best-response rating of complete or partial response or stable disease, according to MPM-modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria

    Time frame: Assessed every 6-12 weeks, up to 100 weeks

  3. Number of Partecipants With Disease Control for ≥ 6 Months

    Measured from the date of randomization until disease progression, or death due to any cause

    Time frame: Assessed every 6-12 weeks, up to 100 weeks

  4. Number of Partecipants With Adverse Events

    All adverse events will be recorded according to CTC version 4.02 (CTC reference: http://ctep.cancer.gov/reporting/ctc.html) on the case report forms (CRFs); the investigator will decide if those events are drug related and his decision will be recorded on the forms for all adverse events.

    Time frame: Assessed every 6-12 weeks, up to 100 weeks

  5. Time to LCSS Symptomatic Progression

    Quality of life (QoL) assessment was performed by using a questionnaire according to The Lung Cancer Symptom Scale (LCSS) . The LCSS is designed as a disease and site-specific measure of QoL particularly for use in clinical trials. It evaluates six major symptoms (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain) associated with lung malignancies and their effect on overall symptomatic distress, functional activities, and global QoL. Within this trial the questionnaire according to LCSS was only recorded by the patient (patient's scale). QoL assessment was performed by using a questionnaire according to LCSS, which consists of nine 100-mm visual analog scales, with scores reported from 0 to 100 (0 representing the best score). The LCSS subscore is the average symptom burden index computed as the mean score for all six major symptoms. Symptomatic progression was defined as a worsening in the average symptom burden index by 25%.

    Time frame: from the date of randomization to the date of the LCSS assessment on which symptomatic progression was identified, assessed on cycle 2, cycle 4 and cycle 6 (each cycle lasted 21 days)

  6. Evaluation of Medical Care Utilization in the Two Treatment Arms

    Medical resource use data collected will be used in health economic analyses where it may be combined with other data from other sources such as cost data or other clinical parameters.

    Time frame: Assessed every 6-12 weeks, up to 100 weeks

07

Results

Posted Sep 17, 2019

Participant flow

Study Period: April 12th, 2010(First enrolment); January 21st, 2013 (date of last enrolment); April 29th, 2014 (cut-off date). 15 clinical sites in Italy, 10 in UK, 7 in USA, 4 in Belgium, 2 in Canada, 2 in Netherland, 2 in Poland, 1 in Egypt, 1 in Ireland;1 in Sweden

Participant flow — Overall Study
MilestoneA: NGR-hTNF + BICB: Placebo+BIC
Started200200
Completed193193
Not completed77
Withdrew: Physician decision10
Withdrew: Death32
Withdrew: Withdrawal by subject35

Outcome measures

PrimaryOverall Survival (OS)

Defined as the time from the date of randomization until the date of death due to any cause or the last date the patient was known to be alive

Time frame:
From date of randomization until the date of first documented progression or date of death from any cause, wichever came first, assesed up to 48 months
Reported as:
Median · months
Overall Survival (OS)
monthsA: NGR-hTNF + BICB: Placebo+BIC
Overall Survival (OS)8.5 (7.2 to 9.9)8.0 (6.6 to 8.9)
Statistical analysis
  • A: NGR-hTNF + BIC vs B: Placebo+BIC · Log Rank · p = 0.58 (The log-rank test (unstratified) was used to compare the two treatment arms. In addition, a stratified version of the log-rank test was performed with the stratification factors used for randomization.) · Hazard ratio (hr): 0.94 · 95% CI 0.75 to 1.18Cox regression analyses (unstratified and stratified) were performed to assess the influence of baseline covariates in an exploratory manner.
SecondaryProgression-Free Survival (PFS)

Defined as the time from the date of randomization until disease progression, or deathdue to any couse or the last patient was konwn to be alive. Progression is defined usind Response Evaluation Criteria In Solid Tumors Criteria (Recist v1.1), as a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition torelative increase of 20% the sum must also demonstrate an absolute increase of at least 5 mm. In addition the appearance of one or more new lesions was also considered progression

Time frame:
From the date of randomization until the date of first documented progression or date of death from any cause, wichever came first, assessed up to 48 months
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsA: NGR-hTNF + BICB: Placebo+BIC
Progression-Free Survival (PFS)3.4 (2.7 to 4.1)3.0 (2.3 to 3.7)
Statistical analysis
  • A: NGR-hTNF + BIC vs B: Placebo+BIC · Log Rank · p = 0.65 · Hazard ratio (hr): 0.95 · 95% CI 0.78 to 1.17Cox regression analyses (unstratified and stratified) was performed to assess the influence of baseline covariates in an exploratory manner.
SecondaryDisease Control Rate (DCR)

Disease control rate (DCR), defined as the percentage of patients who have a best-response rating of complete or partial response or stable disease, according to MPM-modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria

Time frame:
Assessed every 6-12 weeks, up to 100 weeks
Reported as:
Count of participants · Participants
Disease Control Rate (DCR)
ParticipantsA: NGR-hTNF + BICB: Placebo+BIC
Disease control rate (DCR)114109
Complete or partial response (CR o PR)36
Stable disease (SD)111103
Progressive disease (PD)5171
Nonassessable (NA)3520
Statistical analysis
  • A: NGR-hTNF + BIC vs B: Placebo+BIC · Fisher Exact · p = 0.62 · Odds ratio (or): 1.13 · 95% CI 0.76 to 1.68Logistic regression analyses were performed to assess the influence of baseline covariates in an exploratory manner
SecondaryNumber of Partecipants With Disease Control for ≥ 6 Months

Measured from the date of randomization until disease progression, or death due to any cause

Time frame:
Assessed every 6-12 weeks, up to 100 weeks
Reported as:
Count of participants · Participants
Number of Partecipants With Disease Control for ≥ 6 Months
ParticipantsA: NGR-hTNF + BICB: Placebo+BIC
Number of Partecipants With Disease Control for ≥ 6 Months8476
SecondaryNumber of Partecipants With Adverse Events

All adverse events will be recorded according to CTC version 4.02 (CTC reference: http://ctep.cancer.gov/reporting/ctc.html) on the case report forms (CRFs); the investigator will decide if those events are drug related and his decision will be recorded on the forms for all adverse events.

Time frame:
Assessed every 6-12 weeks, up to 100 weeks
Reported as:
Number · participants
Number of Partecipants With Adverse Events
participantsA: NGR-hTNF + BICB: Placebo+BIC
Study-emergent AEs of any grade191185
Study-emergent AEs of grade 310286
Study-emergent AEs of grade 42219
Study-emergent AEs of grade 51213
Treatment-related AEs of grade 500
Treatment discontinuation due to AEs3124
SecondaryTime to LCSS Symptomatic Progression

Quality of life (QoL) assessment was performed by using a questionnaire according to The Lung Cancer Symptom Scale (LCSS) . The LCSS is designed as a disease and site-specific measure of QoL particularly for use in clinical trials. It evaluates six major symptoms (loss of appetite, fatigue, cough, dyspnea, hemoptysis, and pain) associated with lung malignancies and their effect on overall symptomatic distress, functional activities, and global QoL. Within this trial the questionnaire according to LCSS was only recorded by the patient (patient's scale). QoL assessment was performed by using a questionnaire according to LCSS, which consists of nine 100-mm visual analog scales, with scores reported from 0 to 100 (0 representing the best score). The LCSS subscore is the average symptom burden index computed as the mean score for all six major symptoms. Symptomatic progression was defined as a worsening in the average symptom burden index by 25%.

Time frame:
from the date of randomization to the date of the LCSS assessment on which symptomatic progression was identified, assessed on cycle 2, cycle 4 and cycle 6 (each cycle lasted 21 days)
Reported as:
Median · months
Time to LCSS Symptomatic Progression
monthsA: NGR-hTNF + BICB: Placebo+BIC
Time to LCSS Symptomatic Progression3.2 (2.1 to 4.4)3.0 (2.8 to 3.4)
Statistical analysis
  • A: NGR-hTNF + BIC vs B: Placebo+BIC · Log Rank · p = 0.5806 · Hazard ratio (hr): 0.92 · 95% CI 0.68 to 1.26
SecondaryEvaluation of Medical Care Utilization in the Two Treatment Arms

Medical resource use data collected will be used in health economic analyses where it may be combined with other data from other sources such as cost data or other clinical parameters.

Time frame:
Assessed every 6-12 weeks, up to 100 weeks
Reported as:
Count of participants · Participants
Evaluation of Medical Care Utilization in the Two Treatment Arms
ParticipantsA: NGR-hTNF + BICB: Placebo+BIC
ACE INHIBITORS, COMBINATIONS02
ACE INHIBITORS, PLAIN52
ADRENERGICS, INHALANTS710
AMINOGLYCOSIDE ANTIBACTERIALS22
ANESTHETICS, LOCAL04
ANGIOTENSIN II ANTAGONISTS,COMBINATIONS14
ANGIOTENSIN II ANTAGONISTS, plain25
ANTACIDS73
ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES137
ANTIADRENERGIC AGENTS CENTRALLY ACTING02
ANTIADRENERGIC AGENTS PERIPHERALLY ACTING02
ANTIANDROGENS01
ANTIARRHYTHMICS, CLASS I AND III43
ANTIBIOTICS FOR TOPICAL USE04
ANTIDEPRESSANTS172
ANTIDIARRHEAL MICROORGANISMS21
ANTIEMETICS AND ANTINAUSEANTS107110
ANTIEPILEPTICS32
ANTIFIBRINOLYTICS10
ANTIFUNGALS FOR TOPICAL USE20
ANTIGLAUCOMA PREPARATIONS AND MIOTICS01
ANTIGOUT PREPARATIONS1012
ANTIHISTAMINES FOR SYSTEMIC USE6631
ANTIINFECTIVES01
ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COM02
ANTIINFLAMMATORY ANANTIRHEUMATIC PRODUCTSD5865
ANTIMETABOLITES11
ANTIMYCOTICS FOR SYSTEMIC USE1514
ANTIPROPULSIVES48
ANTIPRURITICS32
ANTIPSYCHOTICS73
ANTITHROMBOTIC AGENTS4142
ANTIVERTIGO PREPARATIONS21
ANXIOLYTICS2416
ASCORBIC ACID (VITAMIN C)01
BACTERIAL VACCINES10
BELLADONNA AND DERIVATIVES34
BETA BLOCKING AGENTS AND OTHER ANTIHYPERTENSIVES1115
BETA-LACTAM ANTIBACTERIALS, PENICILLINS3829
BILE THERAPY11
BLOOD AND RELATED PRODUCTS2126
BLOOD GLUCOSE LOWERING DRUGS EXCL. INSULINS26
CALCIUM1912
CAPILLARY STABILIZING10
CARDIAC GLYCOSIDES13
CARDIAC STIMULANTS EXCL CARDIAC GLYCOSIDES10
CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN138108
CORTICOSTEROIDS, PLAIN21
COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS25
COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPEC717
DECONGESTANTS AND ANTIALLERGICS01
DIRECT ACTING ANTIVIRALS22
DIURETICS AND POTASSIUM-SPARING AGENTS63
DRUGS AFFECTING BONE23
DRUGS FOR CONSTIPATION3963
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS35
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REF7471
DRUGS FOR TREATMENT OF TUBERCULOSIS20
DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY41
ECTOPARASITICIDES, INC SCABICIDESL.01
EMOLLIENTS AND PROTECTIVES10
EXPECTORANTS EXCL COMBINATIONS WITH COUGH SUPPR.149
HIGH-CEILING DIURETICS1920
HORMONES AND RELATED AGENTS01
HYPNOTICS AND SEDATIVES1414
HYPOTHALAMIC HORMONES01
I.V. SOLUTION ADDITIVES1721
I.V. SOLUTIONS610
IMMUNOSTIMULANTS2019
INSULINS AND ANALOGUES50
INTESTINAL ANTIINFECTIVES32
IRON PREPARATIONS149
LIPID MODIFYING AGENTS, PLAIN44
LOW-CEILING DIURETICS, EXCL THIAZIDES10
MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS814
MULTIVITAMINS, COMBINATIONS14
MULTIVITAMINS, PLAIN45
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS01
MYDRIATICS AND CYCLOPLEGICS23
OPIOIDS135160
OTHER ANALGESICS AND ANTIPYRETICSD10593
OTHER ANTIANEMIC PREPARATIONS2020
OTHER ANTIBACTERIALS45
OTHER ANTIDIARRHEALS10
OTHER ANTINEOPLASTIC AGENTS02
OTHER BETA-LACTAM ANTIBACTERIALS89
OTHER CARDIAC PREPARATIONS30
OTHER DRUGS FOR ACID RELATED DISORDERS01
OTHER DRUGS FOR OBSTRUCTIVE78
OTHER MINERAL SUPPLEMENTS45
OTHER NUTRIENTS47
OTHER OPHTHALMOLOGICALS01
OTHER PLAIN VITAMIN PREPARATIONS20
OTHER RESPIRATORY SYSTEM PRODUCTS20
OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEA31
OTHER VITAMIN PRODUCTS, COMBINATIONS12
PERIPHERAL VASODILATORS01
POTASSIUM45
POTASSIUM-SPARING AGENTS15
PROPULSIVES6887
PSYCHOLEPTICS AND PSYCHOANALEPTICS01
PSYCHOSTIMULANTS,01
QUINOLONE ANTIBACTERIALS3136
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VA16
STOMATOLOGICAL PREPARATIONS2019
SULFONAMIDES AND TRIMETHOPRIM20
TETRACYCLINES04
THYROID PREPARATIONS20
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN12
UROLOGICALS31
VASODILATORS USED IN CARDIAC DISEASES02
VIRAL VACCINES10
VITAMIN A AND D05
VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN03
VITAMIN B12 AND FOLIC ACID711
VITAMIN K AND OTHER HEMOSTATICS13
SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CA34

Adverse events

Collected over Through study completation, an average of 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
A: NGR-hTNF + BIC12/193 (6.2%)56/193 (29%)190/193 (98.4%)
B: Placebo+BIC13/193 (6.7%)54/193 (28%)185/193 (95.9%)
Most frequent serious events
Showing 10 of 71
Most frequent serious events
EventA: NGR-hTNF + BICB: Placebo+BIC
Uncertain study medication dose deliveredInjury, poisoning and procedural complications4/1939/193
Condition aggravetedGeneral disorders4/1935/193
DyspnoeaRespiratory, thoracic and mediastinal disorders4/1931/193
NeutropeniaBlood and lymphatic system disorders2/1934/193
DeathGeneral disorders3/1932/193
Chest painGeneral disorders3/1933/193
PneumoniaInfections and infestations0/1933/193
ChillsGeneral disorders2/1930/193
PyrexiaGeneral disorders2/1932/193
Drug infusion reactionInjury, poisoning and procedural complications2/1930/193
Most frequent other events
Showing 10 of 31
Most frequent other events
EventA: NGR-hTNF + BICB: Placebo+BIC
ChillsGeneral disorders104/19323/193
FatigueGeneral disorders93/19394/193
PainGeneral disorders91/19389/193
DysponoeaRespiratory, thoracic and mediastinal disorders63/19356/193
NauseaGastrointestinal disorders61/19362/193
NeutropeniaBlood and lymphatic system disorders57/19360/193
Decreased appetiteMetabolism and nutrition disorders46/19351/193
PyrexiaGeneral disorders48/19339/193
CoughRespiratory, thoracic and mediastinal disorders39/19347/193
ConstipationGastrointestinal disorders42/19345/193

Baseline characteristics

Patients ≥ 18 years with advanced malignant pleural mesothelioma previously treated with a pemetrexed based chemotherapy regimen for advanced or metastatic disease.

Age, Categorical
Age, Categorical(Participants)A: NGR-hTNF + BICB: Placebo+BICTotal
<=18 years000
Between 18 and 65 years9287179
>=65 years108113221
Age, Continuous
Age, Continuous(years)A: NGR-hTNF + BICB: Placebo+BICTotal
Median65 (25 to 89)67 (31 to 81)66 (25 to 89)
Sex: Female, Male
Sex: Female, Male(Participants)A: NGR-hTNF + BICB: Placebo+BICTotal
Female445599
Male156145301
Race (NIH/OMB)
Race (NIH/OMB)(Participants)A: NGR-hTNF + BICB: Placebo+BICTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American202
White198197395
More than one race000
Unknown or Not Reported022
Region of Enrollment
Region of Enrollment(participants)A: NGR-hTNF + BICB: Placebo+BICTotal
Canada358
Netherlands527
Sweden112
Belgium5813
United States141226
Ireland314
Egypt171936
Poland171431
Italy7984163
United Kingdom494695
France4610
Spain325
08

Study locations

49 sites
  • Wilshire Oncology Medical Group
    Corona, California 92879, United States
  • City of Hope-Comprehensive Cancer Cente
    Duarte, California 91010, United States
  • H. Lee Moffitt ancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Johns Hopkins
    Baltimore, Maryland 21231, United States
  • Columbia University
    New York, New York 10032, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • UTsouthwestern medical center
    Dallas, Texas 75390, United States
  • Antwerp University Hospital
    Edegem, Antwerp B-2650, Belgium
  • Centre Hospitalier Universitaire de Liège
    Liège, Liege 4000, Belgium
  • Institut Jules Bordet
    Bruxelles, 1000, Belgium
  • Cliniques Universitarie St. Luc
    Bruxelles, 1200, Belgium
  • Universitair Ziekenhuis
    Gent, 9000, Belgium
  • UAB - Alberta Cancer Board - Cross Cancer Institute
    Edmonton, Alberta T6G1Z2, Canada
  • University Health Network, Princess Margaret Hospital
    Toronto, Ontario M5G2C4, Canada
  • National Cancer Institute
    Cairo, 11796, Egypt
  • Hôpitaux de Marseille Hôpital Nord
    Marseille, Cedex 20, France
  • St James's Hospital
    Dublin, Ireland
  • Ospedale Santo Spirito
    Casale Monferrato, Alessandria 15033, Italy
  • Azienda Ospedaliera Universitaria San Luigi Gonzaga
    Orbassano, Torino 10043, Italy
  • Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
    Alessandria, 15100, Italy
  • Centro di Riferimento Oncologico
    Aviano, Italy
  • Ospedale Valduce
    Como, Italy
  • Azienda Ospedaliero-Universitaria Careggi di Firenze
    Firenze, Italy
  • Istituto Nazionale per la Ricerca sul Cancro
    Genoa, 16132, Italy
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-IRST
    Meldola, 47014, Italy
  • Fondazione San Raffaele del Monte Tabor
    Milan, 20132, Italy
  • Azienda Ospedaliera San Gerardo
    Monza, 20052, Italy
  • Istituto Oncologico Veneto
    Padova, Italy
  • Azienda Ospedaliero Universitaria di Parma
    Parma, Italy
  • Azienda Unità Sanitaria locale di Ravenna
    Ravenna, 48100, Italy
  • A.O. Salvini Garbagnate, Ospedale di Rho
    Rho, Italy
  • Azienda Ospedaliera Senese
    Siena, 53100, Italy
  • St. Jansdal Hospital
    Harderwijk, Gelderland 3840, Netherlands
  • St. Antonius Hospital
    Nieuwegein, Utrecht 3435, Netherlands
  • Medical University of Gdansk
    Gdansk, 80211, Poland
  • Maria Sklodowska Memorial Cancer Center and Institute of Oncology
    Warsaw, 02-781, Poland
  • Hospital Universitari Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
  • Hospital Vall d'Hebron
    Barcelona, 08035, Spain
  • The University Hospital
    Linkoping, 581 85, Sweden
  • Chest Clinic, Wythenshawe Hospital
    Manchester, Greater Manchester M23 9LT, United Kingdom
  • Kent Oncology Centre Maidstone Hospital
    Maidstone, Kent ME16 9QQ, United Kingdom
  • University Hospitals of Leicester
    Leicester, Leicestershire LE0116, United Kingdom
  • Mount Vernon Cancer Centre
    Middlesex, Northwood HA6 2RN, United Kingdom
  • Edinburgh Cancer Centre, Western General Hospital
    Edinburgh, Scotland EH4 2XU, United Kingdom
  • The Beatson West of Scotland Cancer Centre
    Glasgow, Scotland G12, United Kingdom
  • The Royal Marsden Hospital
    Sutton, Surrey, United Kingdom
  • Castle Hill Hospital
    Cottingham, Yorkshire HU16 5JQ, United Kingdom
  • Guy's Hospital
    London, SE1 9RT, United Kingdom
  • The Royal Marsden Hospital
    London, SW3 6JJ, United Kingdom
09

References and documents

Publications

  • Gregorc V, Gaafar RM, Favaretto A, Grossi F, Jassem J, Polychronis A, Bidoli P, Tiseo M, Shah R, Taylor P, Novello S, Muzio A, Bearz A, Greillier L, Fontana F, Salini G, Lambiase A, O'Brien M. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2018 Jun;19(6):799-811. doi: 10.1016/S1470-2045(18)30193-1. Epub 2018 May 9. PubMed 29753703 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2010 to primary completion in Apr 2014, 48 months.

Results were first posted in Sep 2019, 5 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2010
First posted
Apr 2, 2010
StartActual
Apr 12, 2010
Primary completionActual
Apr 29, 2014
CompletionActual
Dec 2017
Results first posted
Sep 17, 2019
Last update
Sep 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01098266
Lead sponsor
AGC Biologics S.p.A.
Responsible party
Sponsor
First posted
Apr 2, 2010
Start date
Apr 12, 2010
Primary completion
Apr 29, 2014
Completion
Dec 2017
Results posted
Sep 17, 2019
Last update
Sep 17, 2019

Study contacts

Antonio Lambiase, MD
study director · AGC Biologics S.p.A.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion